Comparison of cross-platform flow cytometry minimal residual disease evaluation in multiple myeloma using a common antibody combination and analysis strategy.
Mathis S et al. Cytometry B Clin Cytom. 2014 Nov 17. doi: 10.1002/cyto.b.21200. [Epub ahead of print].

Clinical Course and Prognosis of Non-Secretory Multiple Myeloma.
Chawla SS et al. Eur J Haematol. 2014 Nov 10. doi: 10.1111/ejh.12478. [Epub ahead of print].

The prognostic value of multiparameter flow cytometry minimal residual disease assessment in relapse multiple myeloma.
Paiva B et al. Haematologica. 2014 Nov 7. pii: haematol.2014.115162. [Epub ahead of print].

Predictors of survival outcomes in phase 1 relapsed or refractory multiple myeloma patients.
Barbee MS et al. Cancer. 2014 Nov 6. doi: 10.1002/cncr.29136. [Epub ahead of print].

The application of Gadopentate-Dimeneglumin has no impact on progression free and overall survival as well as renal function in patients with monoclonal plasma cell disorders if general precautions are taken.
Hillengass J et al. Eur Radiol. 2014 Oct 31. [Epub ahead of print].

The prognostic impact of peripheral blood progenitor cell dose following high-dose therapy and autologous stem cell transplant for hematologic malignancies.
Sauter CS et al. Leuk Lymphoma. 2014 Nov 3:1-7. [Epub ahead of print].

Flow cytometric sensitivity and characteristics of plasma cells in patients with multiple myeloma or its precursor disease: influence of biopsy site and anticoagulation method.
Manasanch EE et al, Leuk Lymphoma. 2014 Oct 30:1-9. [Epub ahead of print]